Despite challenges in the RV market, REV Group's specialty vehicles segment has driven strong earnings, leading to a 74.27% ...

First, reports of Germany’s industrial decline are exaggerated. German manufacturing is, in fact, surprisingly resilient and agile. The energy crisis and supply chain disruption following the Covid-19 ...

Nonfarm labor productivity increased at a 1.2% annualized rate in the fourth quarter. While Q4's gain was softer than the past few quarters, labor productivity rose 2.3% in 2024 and continues to look ...

GE HealthCare Technologies, spun off from General Electric in 2023, has shown significant stock growth. See why I rate GEHC ...

Federal Reserve officials are treading cautiously on interest rates against a backdrop of sturdy US economic activity and a healthy labor market as officials await policy moves from the Trump ...

Shown below are year-end targets for the S&P 500 in 2025 set by various Wall Street banks and research firms. The chart also ...

In an expanding economy, the GDP growth rate will be positive because businesses are growing and creating jobs for greater productivity. A period of contraction will follow when businesses hold ...

Stop and think about how intensely inconvenient and impoverished life would be without the goods and services made possible by oil, along with the remarkable advances in work productivity that ...

That’s still on the low side among affluent countries, although there are some large world economies with lower taxes than the US (this chart shows 2022 data because 2023 numbers aren’t available for ...

The myth of superhuman productivity, forget about the 5 a.m. alarm ... under Mao Zedong has been what the American people remember as “the week that changed the world.” But isn’t that the same for us ...

The chart above shows the cyclically adjusted price-earnings multiple (which compares ... The level of productivity is a key driver of economic growth. US productivity growth soared ahead of the rest ...

Earnings Growth Forecast: 36.6% p.a. Krystal Biotech is trading significantly below its estimated fair value, with earnings projected to grow substantially at 36.6% annually, outpacing the US market.